SREBF2 and hyperlipidemia: Moreover, as shown in Figure 4D, treatment with 0, 2.5, and 5 μM pterostilbene for 48 h significantly decreased the activities of hyperlipidemia-associated transcription factors SREBP2, HNF1α, HIF1α, and Nrf2 dose-dependently as compared with non-treated control cells.